[Different clinical patterns of secondary drug failure in diabetes mellitus type II patients and their significance for diagnosis of secondary sulfonamide resistance].
Peroral sugar-reducing agents have come to be routinely used in type II diabetes mellitus. The chief representatives of this group of preparations are derivatives of sulfonylurea. However, following a certain period of time effective utilization of sulfonylamides, there develops of secondary drug failure in type II diabetic patients. It is shown that patients with secondary failure represent from the clinical pathophysiological and genetic standpoints a heterogenous group.
Gendeleka
G F
GF
D000284:Administration, Oral; D002908:Chronic Disease; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy*; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D007328:Insulin / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D013453:Sulfonylurea Compounds / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D017211:Treatment Failure
D007004:Hypoglycemic Agents; D007328:Insulin; D013453:Sulfonylurea Compounds